Found: 6
Select item for more details and to access through your institution.
Lenalidomide‐based response‐adapted therapy for older adults without high risk myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 5, p. 735, doi. 10.1111/bjh.15700
- By:
- Publication type:
- Article
OMIP‐049: Analysis of Human Myelopoiesis and Myeloid Neoplasms.
- Published in:
- Cytometry. Part A, 2018, v. 93, n. 10, p. 982, doi. 10.1002/cyto.a.23598
- By:
- Publication type:
- Article
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2017, v. 8, n. 7, p. 209, doi. 10.1177/2040620717710171
- By:
- Publication type:
- Article
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e770, doi. 10.1016/j.clml.2022.04.003
- By:
- Publication type:
- Article
Daratumumab-Based Regimens with Prior Carfilzomib in Patients with Relapsed Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S327, doi. 10.1016/j.clml.2019.07.314
- By:
- Publication type:
- Article
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 7, p. 602, doi. 10.1002/ajh.24014
- By:
- Publication type:
- Article